Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS) reported promising initial data from the ARC-20 study evaluating casdatifan (HIF-2a inhibitor) plus cabozantinib (tyrosine kinase inhibitor) in metastatic kidney cancer patients. The combination demonstrated a 46% confirmed overall response rate in patients with minimum 12-week follow-up. Among 24 efficacy-evaluable patients, 4% achieved complete response, 42% partial response, and 50% stable disease, with only 4% showing disease progression. The safety profile was manageable with no unexpected risks among 42 safety-evaluable patients. Based on these positive results, Arcus plans to initiate two key trials: PEAK-1, a Phase 3 study in immunotherapy-experienced patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line patients.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has announced new employment inducement grants. The company's Compensation Committee granted equity awards to two new employees, including: - Options to purchase 13,400 shares at an exercise price of $9.02 per share (closing price as of May 23, 2025) - Restricted stock units (RSUs) to acquire 13,400 shares These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board of Directors in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.

Arcus Biosciences (NYSE:RCUS) has granted equity-based compensation to three new employees as part of their inducement package. The awards include:

- Stock options to purchase 21,250 shares at an exercise price of $8.53 per share (closing price as of May 8, 2025)

- Restricted stock units (RSUs) totaling 10,650 shares

These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's "inducement exception."

Arcus Biosciences (NYSE:RCUS) reported Q1 2025 financial results and pipeline updates. The company ended Q1 with $1.0 billion in cash. Key highlights include upcoming data presentation for casdatifan plus cabozantinib in renal cell carcinoma at ASCO 2025. Previous data showed promising results with >30% confirmed response rates in two cohorts and 9.7-month median PFS in the 50mg cohort. The company plans to initiate PEAK-1 Phase 3 study in Q2 2025. Financial results showed revenues of $28 million (vs $145M in Q1 2024), R&D expenses of $122 million (vs $109M), and a net loss of $112 million (vs $4M). Arcus expects 2025 revenue between $75-90 million and has sufficient funding through initial pivotal readouts for key programs.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focusing on cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for three new employees, including:

• Options to purchase 39,750 shares at $8.11 per share (closing price on April 23, 2025)
• Restricted stock units (RSUs) to acquire 19,950 shares

These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.

Arcus Biosciences (NYSE:RCUS) has announced the upcoming presentation of groundbreaking combination therapy data at the 2025 ASCO Annual Meeting. The presentation will feature results from the Phase 1/1b ARC-20 study evaluating their HIF-2a inhibitor casdatifan in combination with cabozantinib for clear cell renal cell carcinoma (ccRCC).

Dr. Toni Choueiri from Dana-Farber Cancer Institute will present safety and initial efficacy data for the combination of 100mg casdatifan once-daily with 60mg cabozantinib in patients previously treated with immunotherapy. The oral presentation is scheduled for June 1, 2025, during the Genitourinary Cancer session.

The company will host a conference call to discuss the ARC-20 data on June 2, 2025, at 5:00 AM PT. This data supports Arcus's development program, including their Phase 3 PEAK-1 trial and clinical collaboration with AstraZeneca to evaluate casdatifan with volrustomig in immuno-oncology-naive ccRCC patients.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company developing cancer therapies, has scheduled a conference call and webcast for Tuesday, May 6th, 2025, at 1:30 PM PT / 4:30 PM ET. The event will cover the company's financial results and pipeline updates for Q1 2025, ending March 31st.

Investors can join via phone at +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free) using Access Code: 762544, or register online. The webcast and presentation will be available in the Investors & Media section of arcusbio.com, with a replay available after the event.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to six new employees. The Compensation Committee approved stock options for 16,960 shares at an exercise price of $7.04 per share, reflecting the closing price on April 8, 2025. Additionally, the employees received restricted stock units totaling 8,530 shares. These equity awards were issued under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for twelve new employees, consisting of:

• Options to purchase 42,920 shares of common stock at $9.12 per share (closing price on March 24, 2025)
• Restricted stock units (RSUs) for 21,650 shares of common stock

These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.